RxDoctor Payments Data

Eric Bank, MD

Hematology & Oncology · Solvang, CANPI 1720423882

Payments from drug & device makers

$900,253in general payments, 2019–2025

Across 319 payments — averaging $2822.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$294K
  • Pharmacyclics LLC, An Abbvie Company$157K
  • Astrazeneca UK Limited$138K
  • AbbVie$109K
  • Genentech, Inc.$92K
  • Amgen$47K
  • plus $63K from 35 others

What the payments were for

  • Speaking & faculty fees$1515%
  • Food & beverage$2,49889%
  • Education$1385%
  • Other$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900,253 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$3,864,145
Medicare patients
570
Services billed
182,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib44$650,956
XtandiEnzalutamide45$623,081
Lenalidomide31$411,781
TruqapCapivasertib14$299,953
PomalystPomalidomide17$288,638
BesremiRopeginterferon Alfa-2b-Njft17$278,300
TagrissoOsimertinib Mesylate16$268,288
IbrancePalbociclib14$222,255
NubeqaDarolutamide13$165,879
NerlynxNeratinib Maleate13$155,333
Abiraterone Acetate97$80,884
EliquisApixaban97$70,494
XareltoRivaroxaban14$22,576
Acyclovir84$2,127
Anastrozole88$1,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$19$650,95644 claims
Astellas Pharma US IncXtandi$36$623,08145 claims
AstraZenecaTruqap, Tagrisso$294,185$568,24130 claims
PfizerIbrance, Eliquis$25,230$292,749111 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$200$288,63817 claims
BayerNubeqa$20$165,87913 claims
Johnson & JohnsonXarelto$48$22,57614 claims
Lilly USA, LLCOlanzapine$75$17422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Solvang

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →